Neuronetics to Report Third Quarter 2020 Financial and Operating Results and Host Conference Call

Rhea-AI Summary

MALVERN, Pa., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Neuronetics (NASDAQ: STIM) announced the upcoming release of its third quarter 2020 financial and operating results on November 2, 2020, after market close. A conference call to discuss these results will be held at 4:30 p.m. ET the same day, available via webcast on the company’s investor relations website. Participants can join by phone using specific dial-in numbers. Neuronetics focuses on developing products that enhance the quality of life for patients with psychiatric disorders, including the FDA-cleared NeuroStar® Advanced Therapy System for major depressive disorder.

MALVERN, Pa., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that it plans to release third quarter 2020 financial and operating results after market close on Monday, November 2, 2020. The Company will host a conference call to review its results at 4:30 p.m. Eastern Time the same day.

The conference call will be broadcast live in listen-only mode via a webcast on the Company’s investor relations website at ir.neuronetics.com. To listen to the conference call on your telephone, please dial (877) 472-8990 for United States callers or +1 (629) 228-0778 for international callers and reference confirmation code 1872153, approximately ten minutes prior to start time. The replay will be available on the Company's website for approximately 60 days.

About Neuronetics

Neuronetics, Inc. is a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Our first commercial product, the NeuroStar® Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The system is cleared by the United States Food and Drug Administration, or FDA, for the treatment of major depressive disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. Additional information can be found at www.neuronetics.com.

Investor Contact:

Mark R. Klausner
Westwicke Partners
443-213-0501
ir@neuronetics.com

Media Contact:

Meagan Dominic
Vault Communications
610-455-2779
mdominick@vaultcommunications.com

FAQ

What date will Neuronetics release its Q3 2020 financial results?

Neuronetics plans to release its third quarter 2020 financial results on November 2, 2020.

What time is the Neuronetics Q3 2020 conference call?

The Neuronetics conference call to review Q3 2020 results is scheduled for 4:30 p.m. ET on November 2, 2020.

How can I listen to the Neuronetics Q3 2020 conference call?

The conference call will be available via webcast on Neuronetics' investor relations website and by phone at (877) 472-8990 for U.S. callers.

What product does Neuronetics offer for psychiatric disorders?

Neuronetics offers the NeuroStar® Advanced Therapy System, which is FDA-cleared for treating major depressive disorder.

Where can I find more information about Neuronetics?

Additional information about Neuronetics can be found on their website at www.neuronetics.com.